Pharmatek Laboratories Receives DEA Registration for Handling Controlled Substances

Pharmatek Laboratories Receives DEA Registration for Handling Controlled Substances
 
Pharmatek Expands its Capabilities in Providing Comprehensive Drug Development and Manufacturing Services
SAN DIEGO, Feb. 17 /PRNewswire/ -- Pharmatek Laboratories, Inc., a premier contract development and manufacturing organization supporting the pharmaceutical industry, announced that it has successfully met Drug Enforcement Agency (DEA) requirements to be registered for the development and manufacture of Schedule IV and V controlled substances.

"Based on the needs of our clients, Pharmatek has put significant systems in place for the handling, inventory, development and manufacture of controlled substances," said Kevin Rosenthal, Director of Manufacturing.   "Being registered by the DEA validates our facility design, security systems, and procedures for manufacturing, handling, storage and disposal meet the stringent requirements of the DEA."

Controlled substances are designated as Schedule I-V according to their medical use, potential for abuse and safety or dependence liability.  In order to research, manufacture or distribute a controlled substance, a person or entity must be audited and registered by the DEA.

"Our goal is to continue to strive to meet the needs of our existing and prospective clients by adding to our capabilities in pharmaceutical chemistry development and manufacturing," said Timothy Scott, President at Pharmatek.  "As a client-centric organization, our success is predicated on our ability to serve our clients.  We are happy to bring this additional capability to Pharmatek in order to serve that purpose."

About Pharmatek Laboratories, Inc.

Pharmatek Laboratories Inc. is a premier pharmaceutical chemistry development company providing full-service pharmaceutical chemistry product development for the pharmaceutical industry.  Pharmatek focuses on bringing client compounds from discovery to the clinic with services that include compound selection, analytical development, preformulation testing, formulation development, GMP manufacturing, stability storage and testing, and cytotoxic and high-potency development.

Statements contained in this media release which are not historical facts may constitute forward-looking statements.  All forward-looking statements are subject to risks and uncertainties which could cause actual results to differ from those projected including sales forecasts and strategic expansion.  The trademarks Pharmatek, Pharmatek Laboratories, Inc., Hot Rod Chemistry, Pharmatek Formulation Screening, Pharmatek University and PTEK U are all property of Pharmatek Laboratories, Inc.  Additional information about Pharmatek Laboratories may be obtained at the Web site http://www.pharmatek.com or by calling 858-805-6383.

Suggested Articles

Inovio CEO J. Joseph Kim is undeterred by short sellers and other detractors who doubt his company can shuttle a COVID-19 DNA vaccine to market.

Adding entinostat to hormone therapy did not help patients with HR-positive, HER2-negative breast cancer live longer.

The data add to the evidence in support of the IL-6 drug ahead of a FDA decision to approve it in a rare disease served by Alexion’s Soliris.